TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20348164
Drug: Modified tandem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified tandem traction bow appliance (modified TTBA) - Early treatment group
Study: 20348164
Drug: Modified tandem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified tandem traction bow appliance (modified TTBA) - Late treatment group
Study: 20348164
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (observed without treatment for 8 months)
Study: 11778530
Drug: Local chemotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local chemotherapy by fibrobronchoscopy with carboplatin 300 mg combined with intravenous chemotherapy (carboplatin and etoposide regimen)
Study: 11778530
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy with routine carboplatin and etoposide regimen
Study: 7056070
Drug: Drionic device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drionic device treatment for hyperhidrosis
Study: 29087231
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (25 mg)
Study: 22123358
Drug: Tolvaptan (TLV)
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan (TLV) 30 mg
Study: 22123358
Drug: Furosemide (FURO)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (FURO) 80 mg
Study: 22123358
Drug: Tolvaptan (TLV)
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan (TLV) 30 mg and Furosemide (FURO) 80 mg
Study: 14967419
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard-of-care oral hygiene (SOC)
Study: 14967419
Drug: Standard-of-care oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care oral hygiene (SOC) alone
Study: 23703604
Drug: Medication self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication self-management education program (5 sessions including verbal education, 1:1 consultation, practice in medication self-management, and discussion)
Study: 21726257
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg/day) plus aspirin (100 mg/day)
Study: 21726257
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg/day) plus clopidogrel (75 mg/day)
Study: 16393593
Drug: 595 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595 nm cryogen‐cooled pulsed dye laser treatment
Study: 15459593
Drug: Diltiazem ER
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM ER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem ER tablets (240 mg titrated to 360 mg and to 540 mg)
Study: 15459593
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg titrated to 10 mg and to 20 mg)
Study: 15459593
Drug: Diltiazem ER
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM ER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem ER tablets
Study: 8354536
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg) + Propantheline bromide (15 mg) at bedtime
Study: 8354536
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg) at bedtime
Study: 28678033
Drug: Myofascial Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial Release Therapy (MRT)
Study: 30025540
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT)
Study: 24994700
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (n = 34): Chest tubes removed if daily drainage ≤250 ml, regardless of protein content.
Study: 24994700
Drug: Group S:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S: Patients with high protein content preventing removal despite acceptable volume of daily drainage.
Study: 23232895
Drug: Acetazolamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (750 mg/d) + autoCPAP
Study: 20694273
Drug: Warfarin (dose-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted to a target INR of 2.0-3.0)
Study: 20694273
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg bid
Study: 20694273
Drug: Edoxaban (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (both 30 and 60 mg qd)
Study: 20694273
Drug: Edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 30 mg bid
Study: 18245547
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine
Study: 10986213
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg
Study: 9103749
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) American Lung Association quit program plus nicotine anonymous meetings (n = 70)
Study: 8250305
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of famotidine (HS)/20 mg of famotidine (AM)
Study: 8250305
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of famotidine (HS)/placebo (AM)
Study: 8250305
Drug: Placebo (HS)/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (HS)/20 mg of famotidine (AM)
Study: 8250305
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of famotidine (HS)/40 mg of famotidine (AM)
Study: 8250305
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of famotidine (HS)/placebo (AM)
Study: 8250305
Drug: Placebo (HS)/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (HS)/40 mg of famotidine (AM)
Study: 24880672
Drug: Phonosurgery/voice therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonosurgery/voice therapy
Study: 20356558
Drug: 4.5% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5% NaCl solution
Study: 20356558
Drug: 6% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% NaCl solution
Study: 20356558
Drug: 7.5% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% NaCl solution
Study: 27319812
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution (control group)
Study: 19029562
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine plus midazolam (1 mg/kg ketamine + 0.1 mg/kg midazolam; IVKM)
Study: 19029562
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine only (1 mg/kg; IVK)
Study: 12873948
Drug: Tramadol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol plus placebo (100 mg tramadol IM)
Study: 6138055
Drug: Alcohol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.7 g/kg body weight)
Study: 6138055
Drug: Loprazolam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loprazolam (1.0 mg) + Alcohol (0.7 g/kg body weight)
Study: 31189966
Drug: Sulfonylurea treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea treatment (any type)
Study: 27593569
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy sessions
Study: 27593569
Drug: Child-focused therapy
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused therapy sessions
Study: 27593569
Drug: Context-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Context-focused therapy sessions
Study: 22170010
Drug: Candesartan (±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (± thiazide‐diuretics)
Study: 14686231
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir
Study: 31862739
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% ganciclovir
Study: 17668528
Drug: Retinoid-containing combination
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinoid-containing combination regimens with oral antibiotics
Study: 17668528
Drug: Retinoid-containing combination
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinoid-containing combination regimens with topical benzoyl peroxide and antibiotics
Study: 11260098
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous morphine infusion on demand (PCA group)
Study: 7849233
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (solution)
Study: 7849233
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (powder)
Study: 3071461
Drug: Ketanserin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (up to 80 mg daily)
Study: 28562435
Drug: Calcium hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxylapatite (CaHA) treatment
Study: 19102147
Drug: Forearm-suspending band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm-suspending band immobilization and functional exercise therapy
Study: 16907901
Drug: Benzocaine/tyrothricin sucking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine/tyrothricin sucking lozenges with conscious sedation
Study: 3304118
Drug: emepronium (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: emepronium (600 mg/d)
Study: 3304118
Drug: terodiline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: terodiline (50 mg/d)
Study: 28533679
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg alone
Study: 28533679
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg plus EGCG 300 mg on Day 4
Study: 17163254
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no etidronic acid therapy)
Study: 12665756
Drug: Hyoscine‐N‐butylbromide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine‐N‐butylbromide injection
Study: 12665756
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution administered intraluminally
Study: 12665756
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution administered intramuscularly
Study: 10719808
Drug: Late addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late addition of G-CSF
Study: 10719808
Drug: Early addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early addition of G-CSF
Study: 30852486
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine Zhiyi decoction
Study: 22480387
Drug: Olanzapine-fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine-fluoxetine combination (6/50-18/50 mg/d)
Study: 22480387
Drug: Fluoxetine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (50 mg/d)
Study: 22480387
Drug: Olanzapine (6-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (6-18 mg/d)
Study: 9719976
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (TA)
Study: 24325105
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses Ulinastatin (20,000 U/kg)
Study: 24325105
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses Ulinastatin (5,000 U/kg)
Study: 18405788
Drug: Alogliptin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 100 mg
Study: 18405789
Drug: Alogliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 200 mg
Study: 18405788
Drug: Alogliptin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 400 mg
Study: 18405789
Drug: Alogliptin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 800 mg
Study: 9176996
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (+)S-ibuprofen arginine
Study: 9176996
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (−)R-ibuprofen arginine
Study: 9176996
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg racemic ibuprofen arginine
Study: 9176996
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (+)S-ibuprofen arginine and 400 mg (−)R-ibuprofen arginine
Study: 9176996
Drug: (−)R-ibuprofen arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (−)R-ibuprofen arginine
Study: 4037034
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nadolol
Study: 6150945
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nadolol
Study: 24524601
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg qn or other statin equivalent to 20 mg atorvastatin
Study: 18694978
Drug: Load group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Load group (priming dose of 0.07 units of regular insulin per kg body weight followed by 0.07 unit x kg(‐1) x h(‐1) i.v.)
Study: 18694978
Drug: Twice no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice no load group (infusion of regular insulin of 0.14 x kg(‐1) x h(‐1) without a loading dose)
Study: 18694978
Drug: No load
Approvals — FDA: no, EMA: no, PMDA: no
Description: No load group (infusion of regular insulin of 0.07 unit . kg body weight(‐1) x h(‐1) without a loading dose)
Study: 16534238
Drug: OKT3 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OKT3 therapy in addition to tacrolimus
Study: 12751506
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of lidocaine (1% lidocaine, 1 ml)
Study: 10687338
Drug: MS:DM (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS:DM (morphine sulfate and dextromethorphan hydrobromide)
Study: 9494946
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine and abstinence from smoking
Study: 9399390
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg at night
Study: 8444088
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg twice daily
Study: 3023556
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (120 mg/m2 day 1) + etoposide (120 mg/m2 days 3, 5, and 7)
Study: 3023556
Drug: Standard-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose cisplatin (60 mg/m2 day 1) + etoposide (120 mg/m2 days 3, 5, and 7)
Study: 22210576
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg daily)
Study: 19703381
Drug: Overall ECT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall ECT treatment
Study: 28271733
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin Glulisine (IG) once daily (QD)
Study: 28271733
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin Glulisine (IG) three times daily (TID)
Study: 12649711
Drug: Co-amoxiclav 500
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 500 mg amoxicillin/125 mg clavulanic acid t.i.d. for 10 days
Study: 11289194
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg
Study: 9538976
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (LP)
Study: 1287139
Drug: Ofloxacin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (oral administration)
Study: 1287139
Drug: Sulbactam-ampicillin (parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam-ampicillin (parenteral administration)
Study: 31695482
Drug: Inhaled aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aromatherapy with peppermint essence
Study: 16367988
Drug: Methylphenidate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (up to 0.6 mg/kg/day)
Study: 9725543
Drug: Zolmitriptan 20
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolmitriptan 20 mg
Study: 9725543
Drug: Zolmitriptan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (5 mg, 10 mg, 20 mg)
Study: 2567714
Drug: Alternate-day FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day FSH therapy
Study: 20433807
Drug: MF59-adjuvanted subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted subunit vaccine
Study: 10462245
Drug: Non-adjuvanted subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted subunit vaccine
Study: 12621386
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.025 mg/kg)
Study: 12621386
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.15 mg/kg)
Study: 6616987
Drug: verapamil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (0.1 mg/kg i.v., followed by an infusion of 0.01 mg/kg/min)
Study: 24500418
Drug: Tipifarnib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib (200 mg/m² orally every 12 hours)
Study: 22180622
Drug: 3-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimen of intravenous artesunate (given at 0, 24, and 48 hours)
Study: 1686250
Drug: CCK-4 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK-4 (25 μg)
Study: 1686250
Drug: CCK-4 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK-4 (50 μg)
Study: 16351364
Drug: Daily experiences
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily experiences of identity denial
Study: 2183405
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg/day)
Study: 2244556
Drug: Heparin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin followed by warfarin
Study: 2244556
Drug: Aspirin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (80 mg/day) plus heparin and then warfarin
Study: 31739434
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone (8 mg per day/40 mg total for 5 days)
Study: 31739434
Drug: L-lysine aescinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine aescinate (5 mL for group 2 and 10 mL for group 3)
Study: 31739434
Drug: Baseline therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline therapy with lornoxicam (16 mg per day)
Study: 28627217
Drug: Plantar electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantar electrical stimulation therapy (IG: n = 17)
Study: 16397290
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g aspirin, 3 times daily for 6 days
Study: 3539632
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of prostacyclin
Study: 3539632
Drug: Placebo (solvent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (solvent) infusions
Study: 22434343
Drug: Nicotine stimuli
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine stimuli at concentrations of 99 and 134 ng/mL
Study: 14678066
Drug: Lozenge, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge, 2 mg or 4 mg
Study: 3827157
Drug: labetalol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (mean dose = 235 +/- 47.5 mg/day)
Study: 26869339
Drug: Battlefield Acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Battlefield Acupuncture (BFA) protocol, eight-week once weekly ten-needle treatment (n=13)
Study: 26691209
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg three times per day for 28 days)
Study: 26691209
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in combination with prednisolone)
Study: 26691209
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in combination with pentoxifylline)
Study: 21398006
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (808 nm, 100 mW, 60 seconds, 7.64 J/cm²)
Study: 17074107
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg/d plus 5-aminosalicylic acid (5-ASA) 2 g/d
Study: 12736113
Drug: Carboplatin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (300 mg/m(2), i.v., day 1) and cisplatin (100 mg/m(2), i.v., day 2)
Study: 12736113
Drug: Cyclophosphamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (600 mg/m(2), i.v., day 1) and cisplatin (100 mg/m(2), i.v., day 2)
Study: 12736113
Drug: Platinum dose-intensified
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum dose-intensified arm
Study: 3777829
Drug: Netilmicin plus
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin plus metronidazole (administered for one day)
Study: 3777829
Drug: Doxycycline (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (administered for five days)
Study: 28976844
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at site X (over the root apex)